RHOA and breast cancer: Application of the six-miRNA-signature was explored in the TCGA BRCA dataset [18] (n = 762) motivated by: a) similarity between the observed morphological changes in miR-138 modulated UPS cells with previously described changes in breast cancer cells following RHOA/C modulation [17]; and b) prior success in cross-validating the “cinsarc” sarcoma-derived mRNA signature with breast cancer [19].